Guidelines

Uveal melanoma: NCCN provides first pathway-based guidelines


 

EXPERT ANALYSIS FROM THE NCCN ANNUAL CONFERENCE


“Moreover, because the liver is the site of metastasis most often, and is often the exclusive site of metastasis, liver metastasis–directed therapy is considered part of the management of patients with uveal melanoma,” he said, adding that this can involve resection, ablation, chemo/radio embolization, or regional perfusion.”

The NCCN Uveal Melanoma Guidelines were developed by a panel of experts from various institutions based on the available evidence and on consensus; they are category 2A (based on lower-level evidence with uniform NCCN consensus that the intervention is appropriate).

Dr. Barker reported receiving clinical research support from Amgen, Bristol-Myers Squibb, Elekta, Merck, University of California San Francisco, and University of Florida Health Cancer Center Orlando, and serving as an advisor, consultant, or expert witness for Pfizer.

Pages

Recommended Reading

Immunotherapies extend survival for melanoma patients with brain metastases
MDedge Dermatology
Melanoma survival shorter in those given high dose glucocorticoids for ipilimumab-induced hypophysitis
MDedge Dermatology
SPOTme addresses unmet need for skin cancer screening
MDedge Dermatology
Going Digital With Dermoscopy
MDedge Dermatology
Melanoma diagnosis does not deter pregnancy
MDedge Dermatology
Nivolumab plus ipilimumab effective in melanoma brain metastases
MDedge Dermatology
Mohs underutilized for melanoma of head and neck
MDedge Dermatology
Reflectance confocal microscopy: The future looks bright
MDedge Dermatology
Skin signs may be good omens during cancer therapy
MDedge Dermatology
Sunscreens: Survey of the Cutis Editorial Board
MDedge Dermatology